UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

Lonza

L

Lonza

Cell & Gene TherapyBasel, Switzerland
Visit Website

About Lonza

Lonza is one of the world's most important enablers of the pharmaceutical and biotechnology industries, providing the manufacturing infrastructure that allows drug developers to bring complex therapies from laboratory discovery to commercial supply. Founded in 1897 and headquartered in Basel, Switzerland, the company has grown from its origins in electrochemical production into a leading contract development and manufacturing organisation (CDMO), listed on the SIX Swiss Exchange under the ticker LONN.

Biologics & Cell and Gene Therapy Manufacturing

Lonza's core strength lies in biologics manufacturing, where it operates large-scale mammalian cell culture, microbial fermentation, and downstream processing capabilities across facilities in the United States, Europe, and Asia. The company is a principal manufacturing partner for some of the world's best-selling biologics, including monoclonal antibodies and recombinant proteins. Its Ibex Solutions platform offers modular, flexible manufacturing designed to compress timelines and reduce capital requirements for clients developing next-generation therapies.

In recent years Lonza has invested substantially in cell and gene therapy manufacturing, establishing dedicated facilities and capabilities for viral vector production, including lentiviral and adeno-associated virus (AAV) vectors, as well as plasmid DNA manufacturing. These services address the rapidly expanding pipeline of advanced therapy medicinal products (ATMPs) requiring specialist GMP production.

Small Molecule & Specialty Ingredients

Beyond biologics, Lonza has longstanding expertise in small molecule active pharmaceutical ingredient (API) synthesis, including highly potent API handling and peptide manufacturing. Its Capsugel-derived capsule and dosage form business, integrated following the 2017 acquisition, extends its offering into oral drug delivery formats used across multiple therapy areas.

With dozens of manufacturing sites globally and a workforce of tens of thousands, Lonza serves clients ranging from emerging biotech companies to major multinational pharmaceutical groups. Its scale, regulatory track record, and breadth of technical capabilities make it a reference partner across oncology, immunology, rare diseases, and infectious disease programmes.

Further information is available at lonza.com.

Similar Companies

More in Cell & Gene Therapy

A

AOP Orphan

Europe's pioneer in integrated therapies for rare diseases and critical care, AOP Health (trading as AOP Orphan) brings together scientific rigour, clinical development and commercial delivery under one roof. The company operates at the intersection of rare disease medicine and intensive-care medicine, two areas where unmet patient need remains exceptionally high. The therapeutic focus spans cardiology and pulmonology, haemato-oncology, critical care, and advanced therapies. This breadth reflects a deliberate strategy to address conditions that are either underserved by mainstream pharmaceutical investment or require highly specialised clinical management. A patient story programme, including accounts of sepsis survival, illustrates the real-world impact the company seeks to communicate to partners, prescribers and policymakers alike. On the scientific side, AOP Health maintains an active clinical pipeline with new trials entering development, including a study of a novel treatment approach for blood cancers announced in June 2026. The company publishes its research findings and makes its innovation methodology available to industry audiences, reflecting an openness to scientific dialogue that is characteristic of organisations working in rare-disease areas subject to close regulatory scrutiny. AOP Health operates across multiple international locations and participates actively in the global congress calendar, including rare skin disease and haemato-oncology meetings. In June 2026, the company received a Gold award at the WKO Export Awards, recognising its performance as an Austrian exporter with international reach. This recognition underlines its standing as a commercially active, internationally operating pharmaceutical business, not merely a research-stage organisation. Further information is available at aop-health.com.

View profile
B

Biogen

Biogen pioneered the neuroscience field as one of the world's oldest independent biotechnology companies, founded in 1978 by a group of distinguished scientists including Nobel laureate Walter Gilbert. Headquartered in Cambridge, Massachusetts, the company has spent nearly five decades focused almost exclusively on neurological and neurodegenerative diseases, a level of specialisation that sets it apart from diversified pharma peers. Neuroscience Focus and Key Therapy Areas Biogen's portfolio centres on multiple sclerosis, where it holds one of the broadest treatment ranges in the industry, spanning injectable, oral, and infusion therapies. The company also works in spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Its partnership with Eisai produced lecanemab (marketed as Leqembi), an Alzheimer's treatment that received traditional FDA approval in 2023, marking a significant moment in a field that had seen decades of clinical setbacks. Global Scale and Commercial Presence Listed on the Nasdaq under the ticker BIIB, Biogen operates across more than 30 countries, with commercial infrastructure spanning North America, Europe, and Asia Pacific. The company invests heavily in research and development as a proportion of revenue, consistent with its identity as a science-led organisation rather than a marketing-driven one. Its biosimilars division, built through a long-standing collaboration with Samsung Bioepis, gives Biogen a commercial presence in the cost-sensitive biologics market alongside its branded neurology pipeline. Biogen has also expanded into rare disease and neuropsychiatry, reflecting a strategic effort to broaden the neuroscience platform beyond multiple sclerosis as the MS market faces increasing genericisation. The company's gene therapy interests, including assets in-licensed and acquired over recent years, signal further ambition in treating diseases at the molecular level. For professionals in pharmaceutical, biotech, and medical research sectors, Biogen represents one of the most focused large-cap neuroscience organisations operating globally. Further information is available at biogen.com.

View profile
N

Novartis

Novartis ranks among the world's largest pharmaceutical companies, built on the 1996 merger of Ciba-Geigy and Sandoz, two Swiss chemical and pharmaceutical giants with roots stretching back to the nineteenth century. Headquartered in Basel, Switzerland, the company operates across more than 100 countries and employs hundreds of thousands of people globally, making it one of the defining organisations in modern medicine. Innovative Medicines The core innovative medicines division focuses on developing and commercialising patented treatments across a concentrated set of therapeutic areas. Oncology is a particular strength, with the company having established early leadership in targeted cancer therapies, including kinase inhibitors that reshaped haematology. Cardiovascular, immunology, neuroscience, and ophthalmology round out the primary focus areas. The company's cell and gene therapy ambitions are embodied in platforms that have drawn significant industry attention, positioning Novartis at the frontier of advanced therapeutic modalities. Sandoz & the Generics Legacy For much of its post-merger history, Novartis operated a substantial generics and biosimilars business under the Sandoz brand. In 2023, Sandoz was spun off as an independent publicly traded company, sharpening Novartis's focus entirely on patented innovative medicines. The separation reflected a broader strategic decision to concentrate resources where the company sees its strongest long-term competitive position. Novartis is listed on the SIX Swiss Exchange under the ticker NOVN and on the New York Stock Exchange as NVS, giving it access to deep capital markets to fund its substantial research and development programme. The company consistently ranks among the top spenders on pharmaceutical R&D globally, operating research facilities across Europe, North America, and Asia. Radioligand therapy represents one of the newer strategic bets, combining targeted delivery mechanisms with therapeutic isotopes, an area Novartis has pursued through acquisitions and internal development. The company's commercial pipeline and approved portfolio span small molecules, biologics, and cell-based therapies, reflecting the breadth of its scientific capabilities. Further information is available at novartis.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy